Drug Type Monoclonal antibody |
Synonyms anti-CD26 begelomab, Begedina, murine anti-CD26 BT 5/9 + [2] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Graft vs Host Disease | NDA/BLA | EU | - | |
Steroid Refractory Graft Versus Host Disease | Phase 3 | US | 01 Feb 2016 | |
Steroid Refractory Graft Versus Host Disease | Phase 3 | FR | 01 Feb 2016 | |
Steroid Refractory Graft Versus Host Disease | Phase 3 | DE | 01 Feb 2016 | |
Steroid Refractory Graft Versus Host Disease | Phase 3 | IT | 01 Feb 2016 | |
Steroid Refractory Graft Versus Host Disease | Phase 3 | ES | 01 Feb 2016 | |
Steroid Refractory Graft Versus Host Disease | Phase 3 | CH | 01 Feb 2016 | |
Steroid Refractory Graft Versus Host Disease | Phase 3 | GB | 01 Feb 2016 |
Phase 3 | 36 | (BEGEDINA® (Begelomab)) | neuldqnvab(huglviimjz) = tcbjejzhaj kwqjxeelzy (xqklefclzh, lukmduotsa - lscxmhncsg) View more | - | 30 Jan 2020 | ||
Conventional Second-line Treatment (Conventional Second-line Treatment) | neuldqnvab(huglviimjz) = mltyefcsgw kwqjxeelzy (xqklefclzh, otdhfbldky - klaqnojfie) View more | ||||||
Not Applicable | 69 | wqvhclqpkd(ehpieylfwz) = rflfdoetod rdtbcalngz (etmppmglej ) View more | - | 24 Mar 2019 |